Luminex is counting on its xTAG Gastrointestinal Pathogen Panel to help drive revenue growth this year as first adopters make the assay available for routine testing. The revenues should help to revive the Austin, Texas-based company's assay sales, which have declined in recent quarters, due mainly to reimbursement issues.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.